ALK beats analyst expectations on all parameters

Allergy firm ALK is continuing to gain momentum, ending Q1 2022 on a good note after a positive 2021. The company has grown both in terms of operations and on the bottom line.
Photo: ALK / PR
Photo: ALK / PR
by christian bundgaard, translated by catherine brett

The first three months of the year are behind us, and as allergy season looms for hay fever sufferers, ALK has released its Q1 report.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading